# What did the phase 3 trials of bremelanotide show?

Published November 18, 2026 · Updated November 18, 2026 · Data as of November 15, 2026

In two randomized trials in people, bremelanotide raised desire scores and lowered distress about low desire more than placebo. [1] The trials in people enrolled premenopausal women with hypoactive sexual desire disorder (HSDD). [1] The FDA approved bremelanotide as Vyleesi in 2019 for premenopausal women with acquired, generalized HSDD. [2] Nausea, flushing and headache were more frequent than with placebo in both trials in people. [1]

## Key points

- In two randomized trials in people, bremelanotide raised Female Sexual Function Index (FSFI) desire scores more than placebo, by 0.3 and 0.42 points. [1]
- In the same trials in people, bremelanotide lowered distress about low desire more than placebo, in both studies and in the integrated analysis. [1]
- In subgroup analyses of trials in people, desire and distress improved versus placebo across age, weight, BMI and testosterone groups, with few exceptions. [3]
- In the integrated trials in people, nausea occurred in 40% on bremelanotide and 1.3% on placebo. [4] In those trials in people, flushing was 20.3% against 1.3%, and headache was 11.3% against 1.9%. [4] Injection site reactions were also more frequent than with placebo in those trials in people. [4]
- As of November 15, 2026, PepBank holds 100 findings in people for bremelanotide from 20 publications. [5]

## What is bremelanotide's status with the FDA?

The FDA approved [Bremelanotide (PT-141)](https://pepbank.io/p/pt-141) in 2019 under the name Vyleesi. [2] The FDA indication is for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that causes marked distress or interpersonal difficulty. [2] The FDA lists it as not indicated for postmenopausal women, men, or to enhance sexual performance. [2]

As of November 15, 2026, PepBank holds 100 findings in people for bremelanotide from 20 publications. [5] In the [evidence class](https://pepbank.io/methods) of animal studies, PepBank holds 18 findings in animals from 6 publications. [5] Among the [peptides in PepBank](https://pepbank.io/peptides), bremelanotide has 10 registered trials in the trial registry records. [5]

PepBank lists 28 [Bremelanotide (PT-141) studies](https://pepbank.io/p/pt-141/studies) with results where the peptide was the one given. [5] Those studies hold 128 results in PepBank's records. [5]

Curo, a peptide shop with the same owner as PepBank, has a related article. [PT-141 (Bremelanotide): Is It Legal, and Where Do You Buy It in 2026?](https://curo.you/insights/pt-141-melanocortin-agonist-vyleesi)

## How did bremelanotide compare with placebo on desire and distress?

In two randomized trials in people with HSDD, bremelanotide raised Female Sexual Function Index (FSFI) desire scores more than placebo. [1] The differences in these trials in people were 0.3 and 0.42 points, and 0.35 points in the integrated analysis. [1] Distress about low desire changed more than with placebo in people, by -0.37 and -0.29 points, and -0.33 points integrated. [1]

In a trial in people with HSDD, bremelanotide improved Elements of Desire Questionnaire scores more than placebo after 6 months. [6] This held in people for both the monthly and the daily recall versions. [6]

In a dose-finding trial in people with female sexual dysfunctions, pooled bremelanotide raised satisfying sexual events by 0.7 per month, against 0.2 with placebo. [7] In that trial in people, the FSFI total score rose 3.6 points, against 1.9 with placebo. [7] The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score changed by -11.1 points in that trial in people, against -6.8 with placebo. [7]

## Did the results hold across age, weight, BMI and testosterone?

Researchers ran subgroup analyses of the RECONNECT trials in people with HSDD. [3] In those trials in people, bremelanotide improved desire versus placebo across age, weight, BMI and bioavailable testosterone subgroups, with few exceptions. [3] It also reduced distress about low desire in people across the same subgroups, with few exceptions. [3]

## Which side effects were more common than with placebo?

In both trials in people with HSDD, nausea, flushing and headache were more frequent with bremelanotide than with placebo. [1] Each occurred at 10% or more in both studies in people. [1] Most treatment-emergent adverse events in people were about tolerability and were mild or moderate. [1]

Side effects in the integrated double-blind trials

| Side effect | Bremelanotide | Placebo |
| --- | --- | --- |
| Nausea, in trials in people | 40% in people on bremelanotide | 1.3% in people on placebo [4] |
| Flushing, in trials in people | 20.3% in people on bremelanotide | 1.3% in people on placebo [4] |
| Headache, in trials in people | 11.3% in people on bremelanotide | 1.9% in people on placebo [4] |
| Injection site reactions, in trials in people | 5.4 in people on bremelanotide | 0.5 in people on placebo [4] |

## How was bremelanotide given in these trials?

The two randomized controlled trials in people with HSDD used a studied amount of 1.75 mg, given subcutaneously. [1] The subgroup analyses in people looked at the same studied 1.75 mg subcutaneous amount from randomized controlled trials. [3] A randomized controlled trial of blood pressure in people compared studied subcutaneous amounts of 1.25 mg and 1.75 mg. [8]

| Kind | Dose | Species | Route | Design | Source |
| --- | --- | --- | --- | --- | --- |
| Studied dose | 1.75 mg | people | subcutaneous | randomized controlled trial | [1] |
| Studied dose | 1.75 mg | people | subcutaneous | randomized controlled trial | [3] |
| Studied dose | 1.25 mg | people | subcutaneous | randomized controlled trial | [8] |
| Studied dose | 1.75 mg | people | subcutaneous | randomized controlled trial | [8] |

## FAQ

### Is PT-141 the same drug as Vyleesi?

PepBank records the peptide as Bremelanotide (PT-141), with 28 studies with results. [5] The FDA approved bremelanotide under the name Vyleesi in 2019. [2] The FDA indication is for premenopausal women with acquired, generalized HSDD that causes marked distress or interpersonal difficulty. [2] The FDA lists it as not indicated for postmenopausal women, men, or to enhance sexual performance. [2]

### Does bremelanotide raise blood pressure?

In a randomized trial in people with female sexual dysfunction, bremelanotide raised ambulatory systolic blood pressure versus placebo in the first hours after each dose. [8] With the lower studied amount in people, the rises were 2.4 and 3 mmHg. [8] With the higher one in people, they were 3.1 and 3.2 mmHg, and heart rate fell. [8] Diastolic pressure rose in a similar way in people. [8]

### Is bremelanotide safe with alcohol?

In a randomized trial in healthy adults, single intranasal bremelanotide doses with or without ethanol were safe and generally well tolerated. [9] In that trial in people, no clinically significant pharmacokinetic interaction with ethanol was found, overall or by sex. [9] No participants in this trial in people stopped because of adverse events. [9] No drug-related serious adverse events were reported in people. [9]

### Did researchers study PT-141 in men?

In a randomized trial in men with erectile dysfunction, intranasal PT-141 plus sildenafil gave a greater erectile response than sildenafil alone. [10] The combination was well tolerated in people, with no new adverse events. [10] It also showed no increase in frequency or severity of adverse events in people compared with monotherapy. [10] The FDA lists Vyleesi as not indicated for men. [2]

## Sources

1. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and gynecology, 2019-11-01. https://pubmed.ncbi.nlm.nih.gov/31599840/ PMID 31599840. Evidence class: human.
2. Vyleesi (US). U.S. Food and Drug Administration, 2026-10-09. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557
3. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022-02-25. https://pubmed.ncbi.nlm.nih.gov/35230162/ PMID 35230162. Evidence class: human.
4. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022-02-01. https://pubmed.ncbi.nlm.nih.gov/35147466/ PMID 35147466. Evidence class: human.
5. Bremelanotide (PT-141) in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/pt-141
6. Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder. Journal of patient-reported outcomes, 2020-10-08. https://pubmed.ncbi.nlm.nih.gov/33033885/ PMID 33033885. Evidence class: human.
7. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's health (London, England), 2016-05-16. https://pubmed.ncbi.nlm.nih.gov/27181790/ PMID 27181790. Evidence class: human.
8. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Journal of hypertension, 2017-04-01. https://pubmed.ncbi.nlm.nih.gov/27977473/ PMID 27977473. Evidence class: human.
9. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clinical therapeutics, 2017-02-09. https://pubmed.ncbi.nlm.nih.gov/28189361/ PMID 28189361. Evidence class: human.
10. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology, 2005-04-01. https://pubmed.ncbi.nlm.nih.gov/15833522/ PMID 15833522. Evidence class: human.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/what-did-the-phase-trials-of-bremelanotide-show

This is not medical advice.
